Bill Bosch

603 total citations · 1 hit paper
7 papers, 461 citations indexed

About

Bill Bosch is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Bill Bosch has authored 7 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Bill Bosch's work include Prostate Cancer Treatment and Research (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Hormonal and reproductive studies (3 papers). Bill Bosch is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Hormonal and reproductive studies (3 papers). Bill Bosch collaborates with scholars based in United States, Germany and Italy. Bill Bosch's co-authors include Paola Patrignani, Roy D. Altman, Kay Brune, Clarence L. Young, Dieter Naber, Paul R. Nemeth, Hanns Hippius, Azra Hussaini, Ronald Goldwater and Cy A. Stein and has published in prestigious journals such as Journal of Clinical Oncology, Psychopharmacology and Drugs.

In The Last Decade

Bill Bosch

7 papers receiving 441 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology

2015 364 citations Roy D. Altman, Bill Bosch et al. Drugs profile →

Peers

Countries citing papers authored by Bill Bosch

Since Specialization

Citations

This map shows the geographic impact of Bill Bosch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bill Bosch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bill Bosch more than expected).

Fields of papers citing papers by Bill Bosch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bill Bosch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bill Bosch. The network helps show where Bill Bosch may publish in the future.

Co-authorship network of co-authors of Bill Bosch

This figure shows the co-authorship network connecting the top 25 collaborators of Bill Bosch. A scholar is included among the top collaborators of Bill Bosch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bill Bosch. Bill Bosch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate 2017 ·Cancer Chemotherapy and Pharmacology ·Azra Hussaini, Anthony J. Olszanski, Cy A. Stein, Bill Bosch, Paul R. Nemeth	4
2	Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies 2017 ·Clinical Pharmacokinetics ·Ronald Goldwater, Azra Hussaini, Bill Bosch, Paul R. Nemeth	25
3	Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study 2017 ·Urologic Oncology Seminars and Original Investigations ·Cy A. Stein, Richard Levin, Robert Given, Celestia S. Higano, Paul R. Nemeth, Bill Bosch, (unknown), Robert Dreicer	14
4	Absorption of a novel formulation of abiraterone acetate (AA) fine particle (AAFP) under fed and fasted conditions. 2017 ·Journal of Clinical Oncology ·Alexander Papangelou, Anthony J. Olszanski, Cy A. Stein, Yuxin Zhang, Bill Bosch, Paul R. Nemeth	2
5	The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers 2017 ·Oncology and Therapy ·Alexander Papangelou, Anthony J. Olszanski, Cy A. Stein, Bill Bosch, Paul R. Nemeth	7
6	Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology breakdown → 2015 ·Drugs ·Roy D. Altman, Bill Bosch, Kay Brune, Paola Patrignani, Clarence L. Young	364
7	Clozapine in the treatment of 121 out-patients 1989 ·Psychopharmacology ·(unknown), Bill Bosch, Dieter Naber, Hanns Hippius	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact